tbuckley/cabot-search huggingface dataset:
Geographic, Demographic, and Temporal Variations in the Association between Heat Exposure and Hospitalization in Brazil: A Nationwide Study between 2000 and 2015
Authors: Qi Zhao, Shanshan Li, Micheline S.Z.S. Coelho, Paulo H.N. Saldiva, Kejia Hu, Julie M. Arblaster, Neville Nicholls, Rachel R. Huxley, Michael J. Abramson, Yuming Guo
Journal: Environmental Health Perspectives (2019)

Background: Limited evidence is available regarding the association between heat exposure and morbidity in Brazil and how the effect of heat exposure on health outcomes may change over time. Objectives: This study sought to quantify the geographic, demographic and temporal variations in the heat–hospitalization association in Brazil from 2000–2015. Methods: Data on hospitalization and meteorological conditions were collected from 1,814 cities during the 2000–2015 hot seasons. Quasi-Poisson regression with constrained lag model was applied to examine city-specific estimates, which were then pooled at the regional and national levels using random-effect meta-analyses. Stratified analyses were performed by sex, 10 age groups, and 11 cause categories. Meta-regression was used to examine the temporal change in estimates of heat effect from 2000 to 2015. Results: For every 5°C increase in daily mean temperature during the 2000–2015 hot seasons, the estimated risk of hospitalization over lag 0–7 d rose by 4.0% [95% confidence interval (CI): 3.7%, 4.3%] nationwide. Estimated 6.2% [95% empirical CI (eCI): 3.3%, 9.1%] of hospitalizations were attributable to heat exposure, equating to 132 cases (95% eCI: 69%, 192%) per 100,000 residents. The attributable rate was greatest in children <5 years and was highest for hospitalizations due to infectious and parasitic diseases. Women of reproductive age and those ≥60 years had higher heat burden than men. The attributable burden was greatest for cities in the central west and the inland of the northeast; lowest in the north and eastern coast. Over the 16-y period, the estimated heat effects declined insignificantly at the national level. Conclusions: In Brazil's hot seasons, 6% of hospitalizations were estimated to be attributed to heat exposure. As there was no evidence indicating that thermal adaptation had occurred at the national level, the burden of hospitalization associated with heat exposure in Brazil is likely to increase in the context of global warming. https://doi.org/10.1289/EHP3889
THU0258 Diagnostic value of anti-cd74 autoantibodies in axial spondyloarthritis and axial psoriatic arthritis. results of open-label, cross-sectional, controlled, multicenter progress study
Authors: I.Z. Gaydukova, A. Rebrov, A. Maslyanskiy, S. Lapin, E. Vasilenko, V. Mazurov
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The problem of axial spondyloarthritis' (axSpA) differential diagnostics is not solved, especially in the early stages of the axSpA. Therefore, new diagnostic markers for axSpA are needed. <h3>Objectives</h3> of the study were to evaluate the prevalence, sensitivity and specificity of anti-CD74 autoantibodies (anti-CD74-AB) in HLA-B27 associated axSpA in comparison with HLA-B27 associated axial Psoriatic arthritis (axPsA) and with healthy controls. <h3>Methods</h3> Anti-CD74-AB (quantitative ELISA) were measured in serum of 114 HLA-B27-positive patients with axSpA, and in 26 age- and sex – matched HLA-B27 positive patients with axPsA, and in 37 healthy controls without HLA-B27. 68 axSpA patients had ankylosing spondylitis (AS) according mNew-York criteria (1984), 46 axSpA persons had non-radiographic axSpA (nr-axSpA) due to ASAS criteria for axSpA (2009). AxPsA patients had psoriatic arthritis with axial involvement and fulfilled both <sup>CASPAR (2006)</sup> and ASAS axSpA criteria (2009). Disease activity in axSpA and axPsA patients was measured according ASAS recommendations.<sup>1</sup> <h3>Results</h3> Patients with AS, nr-axSpA and axPsA were comparable in SpA activity: differences in BASDAI, ASDAS indices and C-reactive protein levels were not significant, p≥0.05 for all. Nr-axSpA patients had shorter disease duration as compared with AS and axPsA patients (p&lt;0.001). The concentration of anti-CD74-AB in patients with axSpA was 3.5±3.0 U/ml (3.1±3.0 U/ml in AS and 3.8±2.9 U/ml in nr-axSpA patients), 2.1±1.4 U/ml in patients with axPsA (p≥0.05 compared to controls and ax-SpA)) and 1.3±1.4 U/ml in healthy controls (p&lt;0.05 for the difference with ax-SpA, AS and nr-axSpA). Diagnostic values of anti-CD74-AB in axSpA (ROC-analyse results) are presented in table 1. <h3>(ROC-analyse)</h3> Cut-off value of anti-CD74-AB&gt;2.0 U/ml in patients with axSpA showed the diagnostic sensitivity of 64.4%, specificity of 89.2%, the positive LR of 5.9, whereas in patients with nr-axSpA at concentrations of 1.7 U/ml - sensitivity 73.1%, specificity 84% and positive LR 4.5. <h3>Conclusions</h3> <b>Conclusions</b>. Anti-CD74-AB are strongly associated with nr-axSpA and less – axPsA. The measurement of anti-CD74-AB can be considered as candidate biomarker in the diagnostics of axSpA and in differential diagnostics between HLA-B27 positive ax-SpA and axPsA, especially in early stages of the diseases. Further studies are needed for the evaluation of anti-CD74-AB diagnostic capacity. <h3>Reference</h3> [1] Sieper J, et al. Ann Rheum Dis2009Jun;68Suppl 2:ii1–44. <h3>Disclosure of Interest</h3> None declared
SAT0743-HPR Relation between serum albumin and physical performance and mobility in a community-based elderly people with osteoporosis
Authors: M. Karapinar, A. Abit Kocaman, N. Kirdi, B. Balam Yavuz
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Osteoporosis is a disease related to ageing and to other interacting variables, including genetic, metabolic, physical and nutritional factors. Several studies have reported that the serum albumin level in the elderly is significantly associated with muscle mass, muscle strength and functional capacity.<sup>1</sup> Even among a nondisabled older persons, lower albumin concentrations have been shown to be independently associated with poorer performance as assessed by objective physical performance tests.<sup>2</sup> <h3>Objectives</h3> The purpose of this study was to investigate the association of serum albumin with physical performance (muscle strength and mobility ability) in patients with osteoporosis. <h3>Methods</h3> For the study, 168 patients with OP (98 women and 70 men) underwent an interview, physical performance testing and blood analysis. A total of patients followed by Hacettepe University Faculty of Medicine Department of Internal Medicine, Division of Geriatric Medicine Department and Geriatric Rehabilitation Unit. We excluded those who Mini Mental State score is under 24 points, Mini Nutritional Assessment Test score is under 11 and have advanced kidney disease. Physical performance was evaluated with Five Times Sit to Stand (FTSS) and Six Metre Walk Test (SMWT). Hand grip strength was measured with dynamometer. Pearson's correlation coefficients were calculated for serum albumin, FTSS, SMWT and handgrip strength. <h3>Results</h3> Participitants mean age of 72.73±6.34 years and BMI 22.56±2.98 kg/m² mean serum albumin concentration ±standart deviation was 41.9±3.5 g/L for women and 41.9±2.9 g/L for men. Serum albumin was associated significantly with physical performence (mobility and walking speed) and muscle strength (hand grip) were in men and women with OP(p&lt;0.005). <h3>Conclusions</h3> Our study demonstrated that a decrease in the serum albumin level is associated with a decrease in physical performance and muscle strength, although causality is still unclear. <h3>References</h3> [1] Hannan MT, et al. Risk factors for longitudinal bone loss in elderly men and women: the Framingham Osteoporosis Study. Journal of Bone and Mineral Research2000;15(4):710–720. [2] Cabrerizo S, Cuadras D, Gomez-Busto F, Artaza-Artabe I, Marín-Ciancas F, Malafarina V. Serum albumin and health in older people: review and meta analysis. Maturitas2015;81(1):17–27. <h3>Disclosure of Interest</h3> None declared
AB0226 Decline in anti-ccp and rheumatoid factor levels in patients with early rheumatoid arthritis after 2 years of treatment with intensive combination strategies, including prednisolone: the cobra-light trial
Authors: H.D. Folmo, M.M. ter Wee, D. den Uyl, N.P. Konijn, P.J. Kerstens, A.E. Voskuyl, D. van Schaardenburg, M.T. Nurmohamed, M. Boers, W.F. Lems
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Previous studies have proven that the COBRA-light strategy has similar effectiveness and safety as the COBRA strategy in treating early rheumatoid arthritis (RA) patients<sup>1,2</sup>. However, the effect of these strategies on anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) levels remains contradictory. <h3>Objectives</h3> To investigate whether levels of anti-CCP and RF have changed after 2 years of treatment with COBRA or COBRA-light strategy. <h3>Methods</h3> A total of 162 early RA patients were included in a randomised, open-label, multicenter trial and treated with either COBRA or COBRA-light strategy. After 1 year, the treatment protocol ended, and physicians continued treatment according to clinical judgment, aiming at clinical remission. Log-transformation was first performed before running any analyses in case of skewed distribution, and analyses were performed with Generalised Estimated Equations to evaluate the association between the medication strategies and the change of LN anti-CCP and LN RF levels on average over time. <h3>Results</h3> Over 2 years' time, median anti-CCP and RF levels decreased significantly in COBRA (6%, and 24% respectively) and COBRA-light (4%, and 13%, respectively; table 1). Of the 102 anti-CCP positive patients at baseline, 10 (10%) became anti-CPP negative during treatment (5 COBRA vs. 5 COBRA-light). No significant difference between the two treatment strategies on the change of anti-CCP and RF levels over 2 years' time was found. Additionally, a significant association between baseline DAS44 and remaining anti-CCP positive over time was found (OR=1.8; 95% CI: 1.2–2.8). <h3>Conclusions</h3> Both COBRA and COBRA-light strategies lead to substantial decreases in anti-CCP and RF levels over 2 years of treatment. Patients with a higher DAS44 at baseline have higher odds of being anti-CCP positive over 2 years' time. <h3>References</h3> [1] ter Wee MM. Ann Rheum Dis. 2015;74(6):1233–1240. doi:10.1136/annrheumdis-2013-205143 [2] den Uyl D. Ann Rheum Dis. 2014;73(6):1071–1078. doi:10.1136/annrheumdis-2012-202818 <h3>Disclosure of Interest</h3> None declared
THU0013 Downregulation of microrna may contribute to activation of the interferon signalling pathway in the idiopathic inflammatory myopathies
Authors: J.E. Parkes, H. Chinoy, P.J. Day, J.A. Lamb
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The idiopathic inflammatory myopathies (IIM) are a group of rare autoimmune conditions characterised by weakness and inflammation of skeletal muscle. MicroRNA are short single stranded RNA which regulate gene expression by binding to particular target mRNA and suppressing translation or inducing degradation. MicroRNA are known to play a role in muscle homeostasis and immune regulation and therefore may be involved in IIM pathology. <h3>Objectives</h3> To profile both microRNA and mRNA in whole blood samples from polymyositis (PM), dermatomyositis (DM) and inclusion body myositis (IBM) patients compared to non-myositis controls using next generation RNA sequencing. <h3>Methods</h3> Whole blood samples in tempus tubes were collected as part of the myositis research tissue bank held at the University of Manchester. Total RNA was extracted from 7 PM, 7 DM, 5 IBM and 5 non-myositis control samples and both microRNA and mRNA profiles were determined by sequencing on the Illumina HiSeq 4000. <h3>Results</h3> Analysis of microRNA expression identified 19 microRNAs as significantly differentially expressed (DE) (p&lt;0.05) for PM, 11 for DM and 27 for IBM, compared to controls. Analysis of myositis specific autoantibody anti-Jo1 positive cases (four PM and one DM) vs controls identified 18 DE microRNAs, 12 of which were not identified for any of the clinical subgroups. Gene expression analysis identified 129 significantly DE genes for PM (false discovery rate &lt;0.05), 53 for DM, 24 for IBM and 691 for anti-Jo1 compared to controls. Ingenuity pathway analysis (IPA) of RNAseq data identified the most significant canonical pathway as 'Interferon signalling' which was predicted to be upregulated in PM, DM and anti-Jo1 subgroups. The anti-Jo1 subgroup had a higher number of DE genes and a higher activation score in the interferon signalling pathway compared to PM or DM. The IPA tool microRNA target filter was used to match DE microRNA with corresponding DE mRNA predicted or previously observed to be targets. When mRNA targets were filtered for involvement in interferon signalling, two downregulated microRNA targeted two upregulated mRNA in PM and five downregulated microRNA targeted five upregulated mRNA in the anti-Jo1 group as shown in figure 1. No microRNAs targeting mRNA involved in the interferon signalling pathway were identified for DM or IBM. <h3>Conclusions</h3> To our knowledge this is the first mRNA and microRNA profiling study in whole blood from myositis patients using RNA sequencing. Grouping by anti-Jo1 positivity identified different microRNA and increased predicted activation of interferon signalling compared to the clinical subgroups analysed. Our results suggest that increased activation of the interferon pathway in anti-Jo1 positive patients may be due to downregulation of microRNAs which target genes in this pathway. <h3>Disclosure of Interest</h3> None declared
Tafenoquine versus Primaquine to Prevent Relapse of <i>Plasmodium vivax</i> Malaria
Authors: Alejandro Llanos-Cuentas, Marcus V.G. Lacerda, Tran T. Hien, Iván D. Vélez, Chayadol Namaik-larp, Cindy S. Chu, Maria F. Villegas, Fernando Val, Wuelton M. Monteiro, Marcelo A.M. Brito, Mônica R.F. Costa, Raul Chuquiyauri, Martín Casapía, Chau H. Nguyen, Sandra Aruachan, Ratchadaporn Papwijitsil, François H. Nosten, Germana Bancone, Brian Angus, Stephan Duparc, Graham Craig, Victoria M. Rousell, Siôn W. Jones, Elizabeth Hardaker, Donna D. Clover, Lindsay Kendall, Khadeeja Mohamed, Gavin C.K.W. Koh, Viviana M. Wilches, John J. Breton, Justin A. Green
Journal: New England Journal of Medicine (2019)

Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure."
Development of a Pegylated Dimeric Recombinant Factor VIII-Fc Fusion Protein for the Treatment for Hemophilia a Patients
Authors: Bin Liu, Xiaoshan Wang, Xueqin Li, Haixia Yan, Shuya Wang, Xi Zhu, Pengju Wang, Jie Gao, Yali Wang, Hongsheng Su
Journal: Blood (2018)
Screening for Ovarian Cancer
Authors: David C. Grossman, Susan J. Curry, Douglas K. Owens, Michael J. Barry, Karina W. Davidson, Chyke A. Doubeni, John W. Epling, Alex R. Kemper, Alex H. Krist, Ann E. Kurth, C. Seth Landefeld, Carol M. Mangione, Maureen G. Phipps, Michael Silverstein, Melissa A. Simon, Chien-Wen Tseng
Journal: JAMA (2018)

<h3>Importance</h3> With approximately 14 000 deaths per year, ovarian cancer is the fifth most common cause of cancer death among US women and the leading cause of death from gynecologic cancer. More than 95% of ovarian cancer deaths occur among women 45 years and older. <h3>Objective</h3> To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on screening for ovarian cancer. <h3>Evidence Review</h3> The USPSTF reviewed the evidence on the benefits and harms of screening for ovarian cancer in asymptomatic women not known to be at high risk for ovarian cancer (ie, high risk includes women with certain hereditary cancer syndromes that increase their risk for ovarian cancer). Outcomes of interest included ovarian cancer mortality, quality of life, false-positive rate, surgery and surgical complication rates, and psychological effects of screening. <h3>Findings</h3> The USPSTF found adequate evidence that screening for ovarian cancer does not reduce ovarian cancer mortality. The USPSTF found adequate evidence that the harms from screening for ovarian cancer are at least moderate and may be substantial in some cases, and include unnecessary surgery for women who do not have cancer. Given the lack of mortality benefit of screening, and the moderate to substantial harms that could result from false-positive screening test results and subsequent surgery, the USPSTF concludes with moderate certainty that the harms of screening for ovarian cancer outweigh the benefit, and the net balance of the benefit and harms of screening is negative. <h3>Conclusions and Recommendation</h3> The USPSTF recommends against screening for ovarian cancer in asymptomatic women. (D recommendation) This recommendation applies to asymptomatic women who are not known to have a high-risk hereditary cancer syndrome.
Gabriel Weston: Sing a song of lung health
Authors: Gabriel Weston
Journal: BMJ (2019)

Just before Christmas I visited an inspiring class at the Royal Brompton Hospital. Set up 10 years ago, Singing for Breathing offers an alternative to usual lung rehabilitation for people with chronic lung disease. Although many conditions are represented, most participants have chronic obstructive pulmonary disease—no great surprise when it’s currently ranked by the World Health Organization as the fourth biggest cause of death in the developed world, affecting 3.7 million people in the UK.

In one sense, the suffering associated with respiratory disease is special. Breathlessness is something uniquely terrifying, often likened by patients to …
AB0861 Health status in patients with axial spondyloarthritis (AXSPA) as determined by the assessment of spondyloarthritis international society health index (ASAS-HI)
Authors: R. Burgos-Vargas, G. Alva Medina, I. Peláez Ballestas, C. Ramos-Remus, M. Saavedra Salinas, F. Enriquez-Sosa, A. Guilaisne, C. PACHECO-TENA, G. REYES-CORDERO, O. MUÑOZMONROY, M. PIZAÑA-SERNA, L. SANDOVAL-GARCIA, B. Mota Mondragón, L. Silveira Torre, N. SANTANA, F. MERAYO, M. MARADIAGA-CECEÑA
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The ASAS-HI is a new instrument based in the International Classification of Functioning, Disability and Health to assess the impact of axSpA; ASAS-HI has been validated in Mexican patients. <h3>Objectives</h3> To investigate the status of health in Mexican patients with axSpA using the ASAS-HI <h3>Methods</h3> This is multicenter, cross-sectional study of 377/423 patients with axSpA (ASAS criteria) referred by 64 rheumatologists with private or institutional practice across the country in a period of six months. Sociodemographic and clinical data were collected at each site and analysed centrally. <h3>Results</h3> The ASAS imaging arm were fulfilled 87.5% and the clinical by 61.8%; HLA-B27 was positive in 80.1%; 71.6% were males; 51.9% received bDMARDs. Mean ages at onset and diagnoses were 25.8 (9.9) and 32.8 (11.7) years; median age was 41.6 (13.7) years. The correlation between ASAS-HI and BASDAI, BASFI, and EQ-5D was significant. ASAS-HI mean score was 6.4 (4.2); the cut off was six; values below six meant good health, which corresponded to 203 (53.84%) patients. Univariate analysis disclosed significant differences between groups in variables that were significant in the regression models (see below) and in health care coverage, enthesitis, joint counting, glucocorticoids, HLA-B27, sacroiliitis, BASMI, and ASDAS. In the multivariate analysis, two models were associated ASAS-HI: 1) sex, education, comorbidities, joint surgery, and physician global assessment; 2) BASDAI, BASFI, and EQ-5D <h3>Conclusions</h3> ASAS-HI cut off of six identified good health in 46.15% of patients with axSpA. ASAS-HI correlated with other measures of disease activity, functioning, and quality of life. In multivariate analysis, ASAS-HI associated with those measures as we all as with demographic and clinical variables. <h3>References</h3> [1] Kiltz U, van der Heijde D, Cieza A, Boonen A, Stucki G, Ustun B, et al. Developing and validating an index for measuring health in patients with ankylosing spondylitis. Rheumatology (Oxford). 2011;50(5):894–8. [2] Kiltz U, van der Heijde D, Boonen A, Bautista-Molano W, Burgos-Vargas R, Chiowchanwisawakit P, et al. Measuring impairments of functioning and health in patients with axial spondyloarthritis by using the ASAS Health Index and the Environmental Item Set: translation and cross-cultural adaptation into 15 languages. RMD Open. 2016;2(2):e000311. <h3>Acknowledgements</h3> We acknowledge 64 rheumatologists (grupo sacroiliacos) all over the country that participated in the study <h3>Disclosure of Interest</h3> None declared
GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant
Authors: Amit C Nathwani, Edward Tuddenham, Pratima Chowdary, Jenny McIntosh, Doyoung Lee, Cecilia Rosales, Mark Phillips, Jun Pie, Zhou Junfang, Michael M Meagher, Ulrike Reiss, Andrew M. Davidoff, Chris L Morton, Anne Riddell
Journal: Blood (2018)
Fish Consumption During Pregnancy
Authors: Philippe Grandjean, Sally Ann Lederman, Ellen K. Silbergeld
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
DANCR Promotes Metastasis and Proliferation in Bladder Cancer Cells by Enhancing IL-11-STAT3 Signaling and CCND1 Expression
Authors: Ziyue Chen, Xu Chen, Ruihui Xie, Ming Huang, Wen Dong, Jinli Han, Jingtong Zhang, Qianghua Zhou, Hui Li, Jian Huang, Tianxin Lin
Journal: Molecular Therapy (2019)

The prognosis for patients with bladder cancer (BCa) with lymph node (LN) metastasis is poor, and it is not improved by current treatments. Long noncoding RNAs (lncRNAs) are involved in the pathology of various tumors, including BCa. However, the role of Differentiation antagonizing non-protein coding RNA (DANCR) in BCa LN metastasis remains unclear. In this study, we discover that DANCR was significantly upregulated in BCa tissues and cases with LN metastasis. DANCR expression was positively correlated with LN metastasis status, tumor stage, histological grade, and poor patient prognosis. Functional assays demonstrated that DANCR promoted BCa cell migration, invasion, and proliferation in vitro and enhanced tumor LN metastasis and growth in vivo. Mechanistic investigations revealed that DANCR activated IL-11-STAT3 signaling and increased cyclin D1 and PLAU expression via guiding leucine-rich pentatricopeptide repeat containing (LRPPRC) to stabilize mRNA. Moreover, oncogenesis facilitated by DANCR was attenuated by anti-IL-11 antibody or a STAT3 inhibitor (BP-1-102). In conclusion, our findings indicate that DANCR induces BCa LN metastasis and proliferation via an LRPPRC-mediated mRNA stabilization mechanism. DANCR may serve as a multi-potency target for clinical intervention in LN-metastatic BCa.